Carboplatin-oral etoposide personalised dosing in elderly non-small cell lung cancer patients

By Frasci G.   Comella P.   Panza N.   De Cataldis G.   Del Gaizo F.   Pozzo C.   Gravina A.   Ruffolo P.   Cioffi R.   Marcatili P.   Della Vittoria M.   Monfardini S.   Comella G.  

European Journal of Cancer, Vol. 34, Iss. 11, 1998-10 ,pp. : 1710-1714

Elsevier

Access to resources Recommend Favorite

Gemictabine plus carboplatin in patients with advanced non-small cell lung cancer

By Park Se   Jeong Seong   Kyung Sun   Lim Young-Hee   An Chang   Lee Sang   Park Jeong   Bang Soo   Cho Eun   Shin Dong   Lee Jae  

Medical Oncology, Vol. 22, Iss. 4, 2005-12 ,pp. : 359-366

Humana Press, Inc

Access to resources Recommend Favorite

Carboplatin dosing - gender bias and inaccurate estimates of glomerular filtration rate

By Dooley M.J.   Poole S.G.   Rischin D.   Webster L.K.  

European Journal of Cancer, Vol. 38, Iss. 1, 2002-01 ,pp. : 44-51

Elsevier

Access to resources Recommend Favorite

Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma

By                

Oncology Reports, Vol. 35, Iss. 1, 2016-01 ,pp. : 155-162

Spandidos Publications

Access to resources Recommend Favorite

Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma - a multicentre phase I study

By Giannakakis T.   Ziras N.   Kakolyris S.   Mavroudis D.   Androulakis N.   Agelaki S.   Parashos M.   Sarra E.   Dimou T.   Hatzidaki D.   Vlachonikolis J.   Georgoulias V.  

European Journal of Cancer, Vol. 36, Iss. 6, 2000-04 ,pp. : 742-747

Elsevier

Access to resources Recommend Favorite